S&P 500 7,758 +3.58% Nasdaq 26,691 +5.19% Dow Jones 54,037 +2.96% FTSE 100 10,901 +0.30% DAX 26,319 +2.69% Nikkei 225 66,977 +4.72% Hang Seng 25,856 -0.59% WTI Crude 78.92 +4.16% Gold 4,380 +6.94% US 10-Year Treasury Yield 4.66 -0.55% S&P 500 7,758 +3.58% Nasdaq 26,691 +5.19% Dow Jones 54,037 +2.96% FTSE 100 10,901 +0.30% DAX 26,319 +2.69% Nikkei 225 66,977 +4.72% Hang Seng 25,856 -0.59% WTI Crude 78.92 +4.16% Gold 4,380 +6.94% US 10-Year Treasury Yield 4.66 -0.55%

LATEST

As China tightens its tax rules, can Hong Kong remain a magnet for billionaires?●Crude oil prices extend rally amid uncertainty over US-Iran peace talks; Brent hovers near $94 per barrel●How GMH Luxury Responded to Nigeria’s Currency Crisis Without Compromising Its Commitments●Buy or sell: Gift Nifty up despite elusive Iran-Oman deal, Vaishali Parekh recommends three stocks to buy today●From Gift Nifty, US-Iran war to crude oil prices: 7 key things that changed for Indian stock market overnight●Japan posts first current account deficit in nearly 1-1/2 years●Dollar near two-month trough as US inflation data awaited●Australian shares dip as Westpac weighs on banks ahead of RBA decision●As China tightens its tax rules, can Hong Kong remain a magnet for billionaires?●Crude oil prices extend rally amid uncertainty over US-Iran peace talks; Brent hovers near $94 per barrel●How GMH Luxury Responded to Nigeria’s Currency Crisis Without Compromising Its Commitments●Buy or sell: Gift Nifty up despite elusive Iran-Oman deal, Vaishali Parekh recommends three stocks to buy today●From Gift Nifty, US-Iran war to crude oil prices: 7 key things that changed for Indian stock market overnight●Japan posts first current account deficit in nearly 1-1/2 years●Dollar near two-month trough as US inflation data awaited●Australian shares dip as Westpac weighs on banks ahead of RBA decision●

Asia

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Markets-Economic Times · 1h ago · 🇮🇳 India

Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Molbio Diagnostics aims to secure ₹200 crore to enhance its capital expenditures through a new issuance of shares. In tandem, the firm intends to reduce promoter stake by generating ₹740 crore via an offer for sale. With six manufacturing sites worldwide, the company caters to over ninety nations and has seen substantial revenue growth attributed to its tuberculosis diagnostic test kits.

Read the full story at Markets-Economic Times →

More Asia

As China tightens its tax rules, can Hong Kong remain a magnet for billionaires?

Business - South China Morning Post · 16m ago

Crude oil prices extend rally amid uncertainty over US-Iran peace talks; Brent hovers near $94 per barrel

mint - markets · 23m ago

Buy or sell: Gift Nifty up despite elusive Iran-Oman deal, Vaishali Parekh recommends three stocks to buy today

mint - markets · 38m ago

From Gift Nifty, US-Iran war to crude oil prices: 7 key things that changed for Indian stock market overnight

mint - markets · 38m ago